This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bernatsky, S Articles by Clarke, A E Search for Related Content PubMed PubMed Citation Articles by Bernatsky, S Articles by Clarke, A E Social Bookmarking                         What's this?

Headache, Raynaud’s syndrome and serotonin receptor agonists in systemic lupus erythematosus

Montreal General Hospital, 1650 Cedar Avenue, Room L10-424, Montreal, Quebec H3G 1A4, Canada

C A Pineau

Division of Clinical Immunology/Allergy, Montreal General Hospital, PQ, Canada

J L Lee

A E Clarke

Division of Clinical Epidemiology, Montreal General Hospital, Montreal, PQ, Canada; and Division of Clinical Immunology/Allergy, Montreal General Hospital, PQ, Canada

There are potential concerns regarding serotonin receptor agonists in SLE patients with migraine, particularly patients with concomitant Raynaud’s syndrome. We estimated the prevalence of lupusrelated headache and Raynaud’s syndrome in the Montreal General Hospital SLE clinic cohort and evaluated the relationship between these two variables in multivariable logistic regression models, controlling for age, sex, race, SLE duration and the presence of lupus anticoagulant and antibodies to cardiolipin and beta2 glycoprotein I. We also assessed, through chart review in those individuals with both Raynaud’s syndrome and migraine, a history of serotonin receptor agonist use, and any associated worsening vasospasm. Based on Systemic Lupus Activity Measure (SLAM) scores, the cumulative incidence of lupus-related headache in our sample (n 391) was 46.1%; the prevalence of Raynaud’s syndrome was 49.4%. The adjusted odds ratio (OR) for lupus-related headache and Raynaud’s syndrome was 1.7 (95% CI 1.1, 2.5). In addition, there was a strong independent relationship between headache and anti-beta2 glycoprotein I antibodies (adjusted OR 5.6 [95% CI 1.8, 17.0]). The data from our chart review suggest that careful use of serotonin receptor agonists in patients with both Raynaud’s syndrome and migraines may be undertaken, although caution would necessitate that these agents not be used in individuals with very severe Raynaud’s (eg, digital ulcerations, and so on).

Key Words: headache • Raynaud’s syndrome • systemic lupus erythematosus

Lupus, Vol. 15, No. 10, 671-674 (2006)
DOI: 10.1177/0961203306069997


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?